In the other study, four PD-L1-positive NSCLC patients with de novo resistance to EGFR-TKIs were found to have EGFR-TKI-resistant mutations, MET amplification, and K-ras G12D mutations in a genetic profile analysis [26]. This evidence concerns the gene MET and non-small cell lung carcinoma.